13F Holdings
中文EN

MDWD MediWound Ltd. IFRS

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1593984 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-16.1%
TTM net income YoY21.0%
TTM EPS YoY30.7%
Revenue 3-yr CAGR-13.8%
Net income 3-yr CAGR—

Margins

Gross margin19.2%
Operating margin-149.0%
Net margin-140.8%
FCF margin-127.5%
EBITDA margin-145.5%

Returns

ROE-63.9%
ROA-29.9%
ROIC (approx.)-65.6%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio2.33x
Interest coverage-10.27x

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue32.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$16.96M$20.22M$18.69M$26.50M$23.76M
Cost of revenue$13.71M$17.59M$15.11M$13.33M$14.99M
Gross profit$3.25M$2.63M$3.58M$13.16M$8.77M
R&D expense$14.32M$8.88M$7.47M$10.18M$10.26M
SG&A expense$8.45M$8.20M$6.77M$6.92M$6.35M
Operating income-$25.27M-$19.40M-$15.29M-$8.35M-$11.22M
Interest expense$2.46M$12.81M$1.89M$11.64M$2.31M
Pretax income-$23.71M-$30.16M-$6.53M-$19.52M-$13.52M
Income tax$169,000$61,000$185,000$78,000$27,000
Net income-$23.88M-$30.22M-$6.72M-$19.60M-$13.55M
EBITDA-$24.68M-$18.77M-$14.62M-$7.92M-$10.66M
EPS (basic)-2.10-3.03-0.75-3.93-3.48
EPS (diluted)-2.10-3.03-0.75-3.93-3.48
Weighted avg. shares (diluted)11.38M9.96M9.01M4.99M3.89M
Balance sheet
Cash & equivalents$4.80M$9.15M$11.87M$33.90M$11.05M
Short-term investments$48.34M$34.01M$29.84M$0$0
Receivables$1.62M$4.80M$3.70M$9.33M$1.78M
Inventory$4.09M$2.69M$2.85M$1.96M$1.20M
Current assets$59.96M$52.16M$49.70M$45.84M$14.95M
PP&E, netmay include right-of-use assets (IFRS)$18.64M$14.13M$9.23M$2.37M$2.48M
Intangibles$33,000$99,000$165,000$231,000$297,000
Total assets$86.25M$73.50M$66.46M$50.02M$19.74M
Current liabilities$25.71M$26.54M$18.12M$12.06M$10.72M
Total liabilities$42.62M$42.34M$34.86M$39.10M$24.33M
Shareholders' equity$43.63M$31.15M$31.59M$10.91M-$4.58M
Shares outstanding12.84M10.79M9.22M7.24M3.90M
Cash flow statement
Operating cash flow-$16.12M-$13.62M-$10.46M-$11.88M-$8.92M
Capital expenditure$5.50M$6.27M$6.46M$555,000$489,000
Free cash flow-$21.63M-$19.90M-$16.93M-$12.44M-$9.40M
Investing cash flow-$17.95M-$8.40M-$34.32M-$481,000$3.55M
Financing cash flow$29.62M$19.39M$22.92M$35.76M-$1.05M
Depreciation & amortization$591,000$630,000$672,000$426,000$559,000
Stock-based compensation$3.11M$3.14M$1.94M$1.95M$1.67M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.